From: N6-methyladenosine methyltransferases: functions, regulation, and clinical potential
Type | Function | Name/Company | IC50/EC50 | Cancer | Estimated phase I trial start date | References |
---|---|---|---|---|---|---|
Activator | Specific activator | Compound 3 | 117Â nM | ND | ND | [121] |
Inhibitor | Pan-MTase inhibitor | Sinefungin | 2.36μΜ | ND | ND | [121] |
3-deazaadenosine | ND | ND | ND | [129] | ||
Specific inhibitor | Compound 2 | 8.7 μM | ND | ND | [126] | |
UZH1a | 280Â nM | AML | ND | [127] | ||
STM2457/STORM Therapeutics | 16.9Â nM | AML | 2021 | [128] | ||
Accent Therapeutics | ND | AML, NSCLC | 2021, 2022 | [120] |